Quick Dispatch:
Your surmount-1 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial orders ship within 1-2 business days.
Delivery Options:
Order Tracking:
You'll receive a tracking link by email once your surmount-1 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial ships.
Need Help?
Questions about surmount-1 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial, sizing, or delivery? We're just an email away.
Live Shipping Estimates:
Enter your location at checkout to see available shipping methods and costs for surmount-1 tirzepatide Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial in your area.
SURMOUNT Clinical Trials Orals Session
28.51
FDA approves tirzepatide, Eli Lilly's new type 2 diabetes drug, and the company shares an estimated price
25.99
Mounjaro® (tirzepatide) injection and Zepbound® (tirzepatide) injection
21.92
Eli Lilly launches weight-loss drug Mounjaro in India, beats Novo Nordisk to major market
22.45
FDA approves new version of diabetes drug Mounjaro to be sold for weight loss
23.59
Mounjaro measures up to Trulicity in Eli Lilly cardio trial
28.45
Eli Lilly (LLY) Gets Nod to Launch Weight-Loss Drug Mounjaro in Hong Kong
23.70
